Executive Committee: VYNE Therapeutics Inc.

Manager
Positions heldSince
David Domzalski

David Domzalski

59 year

Chief Executive Officer 2020-02-29
President 2020-02-29
Iain Stuart

Iain Stuart

52 year

Chief Tech/Sci/R&D Officer 2020-02-29
Mutya Harsch

Mutya Harsch

51 year

General Counsel 2020-02-29
Corporate Secretary 2020-02-29
Tyler Zeronda

Tyler Zeronda

39 year

Director of Finance/CFO -
Treasurer 2022-02-28

Composition of the Board of Directors: VYNE Therapeutics Inc.

Director
CommitteesSince
Elisabeth Sandoval

Elisabeth Sandoval

63 year

Audit Committee 2019-02-28
Compensation Committee Chair
Governance Committee 2021-10-20
Nominating Committee 2021-10-20
Anthony Bruno

Anthony Bruno

69 year

Compensation Committee 2020-02-29
Governance Committee Chair 2020-02-29
Nominating Committee Chair 2020-02-29
Christine Borowski

Christine Borowski

48 year

Governance Committee 2023-12-31
Nominating Committee 2023-12-31
Pat LePore

Pat LePore

70 year

Governance Committee 2020-09-09
Nominating Committee 2020-09-09
Sharon Barbari

Sharon Barbari

71 year

Compensation Committee 2020-02-29
Audit Committee Chair 2020-02-29
Steven Basta

Steven Basta

60 year

Audit Committee
David Domzalski

David Domzalski

59 year

Director/Board Member 2020-02-29

Former Officers and Directors: VYNE Therapeutics Inc.

Insider
Positions held
SinceUntil
Ray Steitz
Ray Steitz
Human Resources Officer - 2022-06-30
Raymond Steitz
Raymond Steitz
Human Resources Officer 2018-10-31 2022-05-31
Rex Bright
Rex Bright
Director/Board Member 2020-02-29 2022-01-10
Independent Dir/Board Member 2020-02-29 2022-01-10
Andrew Saik
Andrew Saik
Director of Finance/CFO 2020-02-29 2021-06-17
Treasurer 2020-02-29 2021-06-17
Matthew Wiley
Matthew Wiley
Corporate Officer/Principal 2020-08-31 -
Deepa Desai
Deepa Desai
General Counsel 2020-02-29 -
Xiaoming Zhang
Xiaoming Zhang
Corporate Officer/Principal 2015-10-31 2020-02-29
Paul Berns
Paul Berns
Director/Board Member 2017-10-31 2020-02-29
Mark P. Joing
Mark P. Joing
Corporate Officer/Principal 2015-12-31 2020-01-01

Age distribution of managers

Parity Men Women

Male 7
Female 3

Of which Executive Committee

Male 3
Female 1

Of which Directors

Male 5
Female 2

Revisions

1 year Revenue revision
-
4 months Revenue revision
-
1 months Revenue revision
-
1 year EPS revision
-
4 months EPS revision
-
ESG MSCI
-
Logo VYNE Therapeutics Inc.
VYNE Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing differentiated therapies for the treatment of immuno-inflammatory conditions. Its product candidate is VYN201, a locally administered pan-BET inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, a BD2-selective oral small molecule bromodomain and extra-terminal (BET) inhibitor in preclinical development for the treatment of immuno-inflammatory indications. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.
Employees
10
More about the company